GlassScriptPhysician profile
Joel P Brooks
NPI 1629400635
$13,479.33
in general payments reported to CMS, 2019-2025
21 companies · $4,749 in 2025
The $4,749 reported for 2025 was more than what 80% of Pediatric Allergy/Immunology providers received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.00 · 2020: $115 · 2021: $94.63 · 2022: $432 · 2023: $1,424 · 2024: $6,570 · 2025: $4,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,633 · Consulting Fee: $3,719 · Travel and Lodging: $1,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,633.18 |
| Consulting Fee | $3,719.00 |
| Travel and Lodging | $1,389.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,737.64 | 2021-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $3,319.40 | 2023-2025 | |
| Dermavant Sciences, INC. | $2,366.68 | 2023-2024 | Vtama |
| Csl Behring | $943.09 | 2019-2025 | Haegarda, Andembry, Kcentra |
| Biocryst US Sales Co., LLC | $620.64 | 2022-2025 | Orladeyo |
| Pharming Healthcare, INC. | $419.03 | 2023-2025 | Ruconest |
| Organon LLC | $404.89 | 2025 | Vtama |
| Ars Pharmaceuticals Operations, INC. | $278.58 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $230.65 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $200.35 | 2023-2025 | Cuvitru, Takhzyro |
| Alk-Abello, INC | $167.51 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $148.14 | 2024 | |
| Glaxosmithkline, LLC. | $142.05 | 2024-2025 | Nucala |
| Kaleo, INC. | $121.70 | 2024 | Auvi-Q |
| Lilly USA, LLC | $114.38 | 2025 | Ebglyss |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst Pharmaceuticals, INC. | $97.52 | 2020 | |
| Amgen INC. | $77.25 | 2023-2024 | Tezspire |
| Aimmune Therapeutics, INC. | $27.73 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $24.54 | 2025 | Dojolvi |
| Phadia US INC. | $19.78 | 2024 | Immunocap |
| Novo Nordisk INC | $17.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.